Inceptive vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RNA-based vaccines, and gene regulation; raised $100M Series A led by Andreessen Horowitz;
About
Inceptive is a Berlin and San Francisco-based biotechnology company founded in 2021 by Jakob Uszkoreit (former senior scientist at Google Brain and co-inventor of the Transformer architecture), Rhiju Das (Stanford RNA biophysicist), and other co-founders. The company is applying deep learning to the problem of RNA design — predicting and engineering synthetic RNA sequences that fold into specific structures and perform specific biological functions, such as encoding therapeutic proteins (mRNA medicines), silencing disease genes (siRNA, antisense), or regulating cellular behavior through aptamers and riboswitches.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.